1.
|
Phase: Phase IV Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571AUS177, US177, RIGHT Trial, NCT00081926
|
|
2.
|
Phase: Phase IV Type: Treatment Status: Closed Age: 20 to 74 Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571BJP07, NCT00171977
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571ACA09, NCT00171899
|
|
4.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571H2201, NCT00290771
|
|
5.
|
Phase: Phase III, Phase II Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571H2202, NCT00292149
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-043, EUDRACT Number: 2005-005153-22, NCT00320190
|
|
7.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 70 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: NOVARTIS-CSTI5710106, FHCRC-1556.00, NCT00006343
|
|
8.
|
Phase: Phase III Type: Treatment Status: Closed Age: 15 and over Sponsor: NCI Protocol IDs: CLB-80004, CAN-NCIC-S0033, E-S0033, SWOG-S0033, INT-S0033, NCT00009906, S0033
|
|
9.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: NCI Protocol IDs: ACOSOG-Z9001, CAN-NCIC-SRC1, CALGB-ACOSOG-Z9001, SWOG-ACOSOG-Z9001, NCT00041197, UWCC-UW-6303, UWCC-UW-03-8438-A-03, SRC1
|
|
10.
|
Phase: Phase III Type: Treatment Status: Completed Age: 15 to 65 Sponsor: NCI Protocol IDs: ECOG-2993, MRC-LEUK-UKALL-XII, EST-4491, INT-0132, NCT00002514
|
|
11.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: SSGXVIII/AIO, NCT00116935
|
|
12.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571K2301, NCT00124748
|
|
13.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 to 70 Sponsor: Pharmaceutical / Industry Protocol IDs: CSTI571BDE40, NCT00154375
|
|
14.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: CECOG/GIST 1.2.001, CSTI571BIC07, NCT00293124
|
|
15.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 to 75 Sponsor: NCI, Pharmaceutical / Industry Protocol IDs: UCLA-0511009-01, NOVARTIS-CSTI571K2301, EUDRACT-2005-00657-29, FWA00004642, NCT00324636
|
|
16.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2303, NCT00471497
|
|
17.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA180-056, NCT00481247
|
|
18.
|
Phase: Phase III Type: Treatment Status: Completed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CAMN107A2302, NCT00519090
|
|
19.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: EORTC-62005, AGITG-AGO102-GIST, EORTC 62005, ISG-62005, SSG-15, NCT00685828
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 15 and over Sponsor: Protocol IDs: EORTC-62001, EORTC-16003, NOVARTIS-CSTI5710203, NCT00006357
|
|
21.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: NABTC-9908, NCI-01-C-0243, UCLA-0101024, NCT00010049
|
|
22.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCLA-0011009, UCLA-NCI-1870, NCI-1870, NCT00015834, 1870
|
|
23.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 18 and over Sponsor: NCI Protocol IDs: UCLA-0011010, UCLA-NCI-4292, NCI-4292, NCT00015860, 4292
|
|
24.
|
Phase: Phase II, Phase I Type: Treatment Status: Completed Age: 3 to 21 Sponsor: NCI Protocol IDs: PBTC-006, NCT00021229
|
|
25.
|
Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 to 65 Sponsor: Other Protocol IDs: CKTO-2001-03, HOVON-51CML, EU-20132, HOVON-CKTO-2001-03, NOVARTIS-CST1571ANL01, NCT00028847
|